Imbalanced p53–RB signaling triggers cGAS–STING–mediated immune activation in early oral cancer development

NTMT1 (METTL11A) promotes MYC-dependent proliferation and downstream HLA-A suppression in cervical cancer

Findings identify NTMT1 as a candidate regulatory node associated with MYC activation and downstream HLA-A suppression, warranting further mechanistic and in-vivo investigation, and highlighting NTMT1 as a promising candidate for future therapeutic investigation.

A CD109-SMURF2 Axis Diverts EGFR from Degradation to Sustain Oncogenic Signaling and Promote Squamous Cell Carcinoma Invasion and Stemness

TLSB-09 TARGETED P16 KNOCKOUT CONFERS AN IMMUNOSUPPRESSIVE MICROENVIRONMENT IN PRECLINICAL MODELS OF TRIPLE NEGATIVE BREAST CANCER BRAIN METASTASIS

A role for p16 loss as a candidate functional driver of ICI resistance associated with 9p21 loss in TNBC-BM is suggested and warrant further investigation given the need to nominate biomarkers for ICI response to inform patient care.

p53 hotspot mutants attenuate CTL-mediated tumor cell killing through a novel ALKBH5-YTHDF3-PD-L1 pathway

It is found that the oncogenic effect of mutant p53 in vivo is dependent on the tumor immune microenvironment, and restoration of ALKBH5 activation or inhibition of the m6A modification-YTHDF3 axis could potentially reactivate immune surveillance and eliminate tumors harboring mut-p53.

ZC3H13‐mediated m6A stabilization of CCND1 promotes malignant progression and is associated with poor anti‐PD‐1 response in HNSCC

The findings identify ZC3H13 as a potential therapeutic target for improving the efficacy of anti‐PD‐1 treatment in HNSCC and contributes to malignant tumor phenotypes and alterations in immunosuppressvie features.

ZBTB33/RBM15 Axis Upregulates MACC1 to Promote the Malignant Progression of Colorectal Cancer.

Clinically, these findings not only deepen the understanding of m6A-mediated posttranscriptional regulation in CRC but also identify this axis as a promising therapeutic target for overcoming ferroptosis resistance and improving patient outcomes.